Sir, Intraocular injection of bevacizumab for rubeosis capsulare in a pseudophakic eye 'Rubeosis capsulare' is an uncommon condition of neovascularisation within the lens capsule and is not amenable to conventional treatment modalities. 1 Bevacizumab, a humanised monoclonal anti-VEGF antibody is a new modality in the treatment of ocular neovascularisation. We report a rare case of rubeosis capsulare treated successfully with a single dose of intracameral and intravitreal bevacizumab injection.
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Case report
A 68-year-old man with diabetes and hypertension presented with defective vision of 3 months duration in his left eye (LE) after successful cataract surgery 3 years earlier.
His best-corrected visual acuity (BCVA) was perception of light right eye (RE) 6/24 LE. On examination, RE showed a mature cataract and LE had a posterior chamber intraocular lens with extensive neovascularisation and mild fibrous opacification of the posterior capsule, precluding adequate fundus view ( Figure 1a ). There was no angle or iris neovascularisation. Intraocular pressures were normal in both eyes (BE). B-scan ultrasonography showed structurally normal posterior segments in BE.
He was administered 0.05 ml intravitreal and 0.025 ml intracameral bevacizumab in LE after obtaining informed written consent for off-label use of the same. One week later, the posterior capsule neovascularisation had regressed completely (Figure 1b ) with improved media clarity and BCVA had improved to 6/9. Fundus examination showed proliferative diabetic retinopathy in LE for which laser pan-retinal photocoagulation (PRP) was done. The LE remained stable with no recurrence of neovascularisation at 3, 6 months and 1-year follow-up.
Comments
Bevacizumab has been successful in the treatment of rubeosis iridis and neovascular glaucoma by both intravitreal 2,3 and intracameral routes. 4 It is also efficacious in the treatment of anterior chamber neovascular membrane.
5 MEDLINE search showed a single report on the use of single-dose intravitreal bevacizumab in the treatment of rubeosis capsulare with concomitant iris neovascularisation. 6 In our patient Nd:YAG laser capsulotomy at presentation would have caused bleeding and precluded laser PRP. A single injection of intracameral and intravitreal bevacizumab resulted in the dramatic resolution of the posterior capsule neovascularisation within a week. The improvement in media clarity made laser PRP possible even without Nd:YAG capsulotomy.
In summary, bevacizumab offers a new effective option in the treatment of the rare condition of rubeosis capsulare.
